The Baker Heart and Diabetes Institute has sold clinical research subsidiary Nucleus Network to Crescent Capital Partners. The institute holds an option on 20 per cent of the business but it will, “invest a large percentage of the sale proceeds to underpin the long-term financial stability of the Institute.” Good-o but how much that might be is not known. The Baker declines to disclose the sale price.